-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1909 A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Program: Oral and Poster Abstracts
Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research, Genetic Disorders, Bioinformatics, Diseases, Computational biology, Technology and Procedures, Omics technologies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Naser Ansari-Pour, PhD1*, Mohammad Kazeroun1*, Seyed Alireza Hasheminasab, PhD1*, Emma J Lyon2*, Bethan Hudson-Lund2*, Evie Fitzsimons2*, Gaurav Agarwal, MD3*, Kara-Louise Royle4*, Matthew W. Jenner5*, Martin F Kaiser, MD6, Karthik Ramasamy, MD, PhD7,8, Kwee Yong, MD, PhD2, Eileen M Boyle, MBChB, PhD2, Sarah Gooding, MD, PhD1,9,10*, Angela Hamblin, MD, PhD1,10* and Anjan Thakurta, PhD1

1Oxford Translational Myeloma Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, United Kingdom
2UCL Cancer Institute, University College London, London, United Kingdom
3Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cambridge
4Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
5University Hospital Southampton, Southampton, United Kingdom
6The Institute of Cancer Research, London, ENG, United Kingdom
7Oxford Translational Myeloma Centre, NDORMS University of Oxford, Department of Haematology, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom
8Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, Oxford, United Kingdom
9MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, ENG, United Kingdom
10Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Chromosomal copy number aberrations (CNAs) are common in multiple myeloma (MM) and play a major role in patient prognosis and treatment outcome. Detection of CNAs is possible using targeted region sequencing (TRS), however, accurate detection and quantification of the total copy number and the subclonal fraction of each targeted genomic region is challenging, especially in low-purity samples. Using the Myeloma Genome Project (MGP) Panel [PMID:35522533], we have developed a segmentation-based CNA calling approach for TRS to (a) identify copy number breakpoints, (b) estimate total copy number and its subclonal fraction (defined as significant deviation from expected clonal state), based on tumor coverage ratio (LogR) normalized by its paired germline sample and (c) adjust for the purity of the tumor sample as estimated from the TRS panel single nucleotide variant (SNV) data.

We initially used a set of 27 longitudinal samples from 14 MM patients with both TRS and whole-genome sequencing (WGS) data to optimize the method for accuracy. Results showed a high concordance (96.3%) in total copy number in the targeted regions between WGS (by using Battenberg) and TRS. Cohen’s Kappa between the two was 0.93 (95%CI 0.84-1), showing strong agreement between TRS and gold-standard WGS calls. In addition to standard calling of gain and deletion events even in tumors with purity as low as 17%, the method could also differentiate different total copy number states (e.g. distinguishing between Gain1q and Amp1q). We could detect subclonal events with CCF > 0.3 in tumors with a minimum purity of 50%. The ability to detect CCF depended on sample sequencing evenness as quantified by mean absolute difference of LogR across the genomic regions of the panel (MAD(LogR)<0.3). Our method also allowed the detection of biallelic (e.g., Del17p-TP53) and combinatorial (e.g., Gain1q-Del1p) events in myeloma.

To validate this method, the same analysis was then undertaken on two independent, recently generated TRS datasets (Oxford dataset, N=48 and the UK RADAR clinical trial, N=80), albeit with single time-point samples. Similar frequencies of high-risk CNAs were identified in the validation datasets (Del1p32-p12, Gain1q21, Amp1q21 and Del17p at 23%, 23%, 4% and 15% in the Oxford dataset and 19%, 28%, 6% and 20% in the RADAR dataset respectively) which also match well with previous reports, corroborating the utility of the developed CNA calling method. Altogether, these results demonstrate that this computational method accurately detects CNAs with prognostic value. Also, with the increasing use of subclone size to define high-risk myeloma in new myeloma high-risk guidelines, our method may enable better risk stratification from TRS data at diagnosis. This method has the potential to be applied to other hematological cancer targeted panels to call accurate CNA in the regions targeted by NGS panels.

Disclosures: Kaiser: Poolbeg: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; GSK: Consultancy; Sanofi: Consultancy; Pfizer: Consultancy, Honoraria; Roche: Consultancy; J&J/Janssen: Consultancy, Honoraria, Research Funding; Regeneron: Consultancy. Ramasamy: Amgen, Celgene (BMS), GSK, Janssen, Takeda: Research Funding; AbbVie, Adaptive Biotechnologies, Amgen, Celgene (BMS), GSK, Janssen, Karyopharm, Oncopeptides, Pfizer, Sanofi, Takeda Recordati pharma, Menarini Stemline: Honoraria; AbbVie, Adaptive Biotechnologies, Amgen, Celgene (BMS), GSK, Janssen, Karyopharm, Oncopeptides, Pfizer, Sanofi, Takeda, Recordati pharma, Menarini Stemline: Speakers Bureau; Pfizer, GSK: Membership on an entity's Board of Directors or advisory committees. Gooding: GSK, J&J: Honoraria.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH